Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib

Development of drug responsive biomarkers from pre-clinical data is a critical step in drug discovery, as it enables patient stratification in clinical trial design. Such translational biomarkers can be validated in early clinical trial phases and utilized as a patient inclusion parameter in later s...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bin, Shin, Hyunjin, Gulbekyan, Georgy, Pustovalova, Olga, Nikolsky, Yuri, Hope, Andrew, Bessarabova, Marina, Schu, Matthew, Kolpakova-Hart, Elona, Merberg, David, Dorner, Andrew, Trepicchio, William L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480971/
https://www.ncbi.nlm.nih.gov/pubmed/26107615
http://dx.doi.org/10.1371/journal.pone.0130700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480971/
https://www.ncbi.nlm.nih.gov/pubmed/26107615
http://dx.doi.org/10.1371/journal.pone.0130700

Ejemplares similares